GlassScriptPhysician profile
Ronen Arai
NPI 1982641866
$1,057,234.12
in general payments reported to CMS, 2019-2025
50 companies · $243K in 2025
The $243K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92K · 2020: $31K · 2021: $96K · 2022: $141K · 2023: $156K · 2024: $298K · 2025: $243K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $574K · Consulting Fee: $52K · Travel and Lodging: $44K · Food and Beverage: $26K · Honoraria: $1,110 · Education: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $574,231.36 |
| Consulting Fee | $51,613.00 |
| Travel and Lodging | $43,550.29 |
| Food and Beverage | $26,377.03 |
| Honoraria | $1,110.00 |
| Education | $343.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $291,192.55 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $215,543.00 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $170,901.93 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $109,441.24 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $92,502.67 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $76,646.77 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $34,685.19 | 2023-2025 | Omvoh, Zepbound |
| Celltrion USA INC. | $15,748.42 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14,090.39 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $13,911.74 | 2024-2025 | Voquezna |
| Eli Lilly and Company | $8,395.09 | 2021-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $3,542.84 | 2019-2023 | Rebyota |
| Celgene Corporation | $3,353.40 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $2,059.48 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $742.74 | 2022-2025 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $697.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $559.04 | 2019-2025 | Resolution 360 Ultra Clip, General - Hemostasis, Spyglass |
| Allergan, INC. | $494.88 | 2019-2020 | |
| Ucb, INC. | $261.28 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $217.07 | 2019-2025 | Linzess |
| Gilead Sciences, INC. | $209.81 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $195.02 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $185.34 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $170.10 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $167.63 | 2021-2022 | |
| Redhill Biopharma INC. | $164.93 | 2020-2022 | |
| Shire North American Group INC | $157.51 | 2019 | |
| Braintree Laboratories, INC. | $154.39 | 2019-2020 | |
| Vivus LLC | $95.98 | 2021-2024 | Pancreaze |
| Fresenius Kabi USA, LLC | $76.27 | 2023-2024 | Idacio |
| Alfasigma USA, INC. | $71.77 | 2020-2021 | |
| Qol Medical, LLC | $59.17 | 2021-2024 | Sucraid |
| Cumberland Pharmaceuticals, INC. | $58.52 | 2019-2023 | Kristalose |
| Evoke Pharma, INC. | $51.45 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $46.84 | 2019-2021 | |
| Biocon Biologics INC | $45.96 | 2025 | Yesintek |
| Organon LLC | $41.78 | 2021-2024 | Renflexis |
| Shionogi INC | $41.73 | 2019 | |
| Endo Pharmaceuticals INC. | $38.97 | 2019-2021 | |
| Capsovision, INC. | $36.65 | 2023 | Capsocam Plus |
| Cook Medical LLC | $25.51 | 2020 | |
| Daiichi Sankyo INC. | $24.91 | 2020 | |
| Amgen INC. | $23.18 | 2023 | Amjevita |
| Mylan Institutional INC. | $22.45 | 2023 | Hulio |
| Ambu INC. | $19.98 | 2020 | |
| Vibrant Gastro, INC. | $19.08 | 2024 | Vibrant Starter Kit |
| Medtronic, INC. | $16.16 | 2021 | |
| Covidien LP | $13.29 | 2019 | |
| Pharmacosmos Therapeutics INC. | $12.46 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronen Arai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.